Fusogenic Peptides for Delivery of RNAi Therapeutics to Ovarian Cancer


The novel fusogenic peptides improve the delivery of therapeutics for ovarian cancer through their ability to enhance endosomal escape and delivery of bioactive therapeutics. Epithelial ovarian cancer is the 5th leading cancer among women, with a 49% five-year survival rate. Current treatment strategies for ovarian cancer include surgical removal, chemotherapy, and radiation; however, these treatments often prove ineffective or toxic…

Machine Learning Algorithm to Guide Cardiac Resynchronization Therapy Personalization

Manufacturing, Biotechnology

­This patient risk-assessment machine learning algorithm predicts patient response to cardiac resynchronization therapy (CRT) intervention enabling more informed selection criteria and improved rates of therapy success. Approximately 90,000 patients receive cardiac resynchronization therapy per year, with only 50% of that population benefitting. This directly results from the uncertainties surrounding which patients will actually benefit from the procedure. Providing insights into…
Get Started
Ready to Get Started?

Contact our team at CURF

Contact CURF